NCT06493227 Extended Perioperative Administration of Fibrinolysis Inhibitors After Cardiac Surgery
| NCT ID | NCT06493227 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Saint Petersburg State University, Russia |
| Condition | Thoracic Surgery |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,373 participants |
| Start Date | 2024-08-01 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,373 participants in total. It began in 2024-08-01 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
PRIORITY is a pragmatic, multi-center, cluster crossover trial that aims to evaluate whether implementing a policy of routine extended (intraoperative and 4 hour after transfer to ICU) use of fibrinolysis inhibitors leads to a decrease in post-operative blood transfusion compared to a policy that only involves intraoperative use.
Eligibility Criteria
Inclusion Criteria: 1. A hospital that performs a minimum of 250 open heart interventions per year. 2. Consent from hospital physicians regarding the prophylactic use of fibrinolysis inhibitors (more than 95% of physicians involved in the treatment of adult patients (\>18 years) agree to adhere to the strategy of using fibrinolysis inhibitors as prescribed by the study protocol). Exclusion Criteria: * Hospital does not meet inclusion criteria
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06493227 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Thoracic Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06493227 currently recruiting?
Yes, NCT06493227 is actively recruiting participants. Contact the research team at efremovsergm@gmail.com for enrollment information.
Where is the NCT06493227 trial being conducted?
This trial is being conducted at Saint Petersburg, Russia, Saint Petersburg, Russia.
Who is sponsoring the NCT06493227 clinical trial?
NCT06493227 is sponsored by Saint Petersburg State University, Russia. The trial plans to enroll 1,373 participants.